drugset

drugset / Trial / NCT00230828

Patient-reported Outcomes in the Treatment of Schizophrenia

NCT00230828 ↗

Phase 3 Completed Solvay Pharmaceuticals

Non-randomizedParallel-groupDouble-blindTreatment

Summary

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Timeline

Start: 2005-05
Primary completion: 2006-01
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bifeprunox	Small molecule	—	—

Indications